We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Out of stock
SKU
100313
How can I help you? Free UK delivery over £0 Discreet Delivery Always
Buscopan lBS Relief is a tablet containing hyoscine butylbromide. This medicine is to relieve the abdominal cramps which cause pain and discomfort associated with Irritable Bowel Syndrome. It belongs to a group of medicines called antispasmodics. It works by relaxing the cramping muscles of your bowel.
Irritable Bowel Syndrome is often just called "IBS". While the precise cause is unknown, the muscles of the bowel appear to be very sensitive to things like: * Stress, eating and drinking habits * Food allergies or intolerances * Stimulants such as coffee * Hormonal factors
Such things can trigger painful abdominal cramps or spasms if you have a sensitive bowel. You may also feel bloated, with excess wind and abdominal discomfort. Sometimes IBS can include diarrhoea or constipation.
Product Information
Buscopan lBS Relief is a tablet containing hyoscine butylbromide. This medicine is to relieve the abdominal cramps which cause pain and discomfort associated with Irritable Bowel Syndrome. It belongs to a group of medicines called antispasmodics. It works by relaxing the cramping muscles of your bowel.
Irritable Bowel Syndrome is often just called "IBS". While the precise cause is unknown, the muscles of the bowel appear to be very sensitive to things like: * Stress, eating and drinking habits * Food allergies or intolerances * Stimulants such as coffee * Hormonal factors
Such things can trigger painful abdominal cramps or spasms if you have a sensitive bowel. You may also feel bloated, with excess wind and abdominal discomfort. Sometimes IBS can include diarrhoea or constipation.
Write Your Own Review
-
Offer area
25% Discount New Register User
Code: NewO4PUser-25
-
Offer area
Offer20
Code: Offer20
-
Offer area
Get 20% off all products
Code: Summer20 Valid till:31st August 2025.





